Association between single-pill combination therapy use and blood pressure control in the Systolic Blood Pressure Reduction Intervention Trial: a post hoc analysis
Primary result · Achieving target BPResult — go to the resultOdds ratio 1.22 95% CI 1.05–1.42Authors' conclusion
Single-pill combination use resulted in greater likelihood of achieving target BP control and more rapid, sustained BP reduction without an increase in SAEs.
Study context
- Population
- SPRINT participants with hypertensionmatched cohort
- Participants
- 2,736 participants
- Comparison
- Single-pill combination (SPC) vs equivalent multi-pill therapy
- SPCn = 912
- Multi-pill therapyn = 1,824reference
- Primary endpoint
- Achieving target blood pressure (BP) control
- Follow-up
- 6 months
Methodological detailspost hoc analysis, propensity-score matched (1:2)
- Post hoc analysis
- Propensity-score matched (1:2)
Primary result
Achieving target BP
Odds ratio
1.22
95% CI 1.05–1.42
SPCvs Multi-pill therapy
OR 1.22 (95% CI 1.05–1.42)
As reported in the abstract
Further findings
Monthly change, mmHg
| Outcome | SPC | Multi-pill therapy | P value |
|---|---|---|---|
| Monthly BP change, first 6 months · ≤6 months | −2.0 | −1.2 | P-diff < 0.001 |
| SPC prescription at baseline (all SPRINT participants)Intensive vs Usual care | P-diff < 0.001 |
- SPC prescription at baseline (all SPRINT participants) — Prescribed SPC at baseline
- 9.3% (n = 803) of n = 8623
- SPC prescription at baseline (all SPRINT participants): Intensive 5.79 per 100 person-months
- SPC prescription at baseline (all SPRINT participants): Usual care 3.90 per 100 person-months
SBP over long-term follow-up · >6 months
- Significantly lower SBP at each time point with SPC
Primary CV composite endpoint
- Not significantly different between groups
Safety
Serious adverse events (SAEs)
- Not significantly different between groups
Original publication
Association between single-pill combination therapy use and blood pressure control in the Systolic Blood Pressure Reduction Intervention Trial: a post hoc analysis. Eur J Prev Cardiol. Published 20 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →